Ophthalmology

The director of clinical research at Sierra Eye Associates discussed unmet needs in patients with wet AMD.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending November 18, 2022.

Editas has paused enrollment in the BRILLIANCE trial after efficacy was only seen in a very small subset of patients.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

4D Molecular Therapeutics plans to initiate enrollment in the phase 2 randomized portion of the study in the first quarter of 2023.

The Genomics and Epigenetic Guided Safe Harbor mapper will aid in the future design of gene-editing therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Among the trial’s high dose cohort, 80% of patients did not require supplemental injections for over 2 years.

Review top news and interview highlights from the week ending November 4, 2022.

Updated data from the ALTITUDE trial were presented at the 55th ARS meeting in Pasadena, CA.

Neurotech has announced updated data from protocol A and B phase 3 studies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Studies have demonstrated positive data that suggest in vivo gene editing will be the future treatment paradigm for retinal diseases.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

As we learn more about genomics and identify more genes tied to rare disorders, the role of genetic counselors will become even more critical.

The grant goes toward developing an innovative approach to gene-agnostically and autonomously regulate pressure.

Review top news and interview highlights from the week ending October 21, 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The executive director of Hemophilia Foundation Southern California discussed issues with minorities accessing care for rare diseases and strategies to mitigate them.

With so many therapies on the horizon, the clinical and patient communities need to be adequately prepared to support them.

Future data from other participants with LCA enrolled in the phase 1/2 study will be announced at a later date.

The professor of ophthalmology at the University College London Institute of Ophthalmology discussed the likely rise of gene therapies in inherited retinal diseases.

OCU400 utilizes Ocugen’s modifier gene therapy platform, which may allow the product to treat multiple retinal diseases.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The therapy was previously granted orphan drug designation for both RP and Stargardt disease.

Both botaretigene sparoparvovec and JNJ-81201887 were well-tolerated in treated patients, according to data from the 2022 AAO meeting.

Significant improvements were reported in full-field stimulus testing.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.